PetVivo Holdings, Inc. (OTCMKTS:PETV)
MINNEAPOLIS, MN, US, January 11, 2019 /EINPresswire.com/ -- OTCMARKETS: (PETV) PetVivo Holdings, Inc. (www.petvivo.com) an emerging biomedical device company operating in the $18B veterinary market announced today it will be exhibiting at the Veterinary Meeting & Expo Conference from January 20th to January 23rd, 2019 at the Orange County Convention Center in Orlando, FL.
PetVivo is excited to meet with many of the 15,000+ participants to talk about its lead product, an injection of sterilized, hydrogel microparticles that are wet, slippery and spongy for the treatment of osteoarthritis and lameness originating in the joints of dogs and horses. VMX is the largest veterinary conference in the United States, and plays host to many of the top industry professionals.
“PetVivo is excited to network with leaders in the industry and develop relationships that will help drive our product forward,” said John Carruth, Acting CFO of PetVivo Holdings, Inc. “I believe our product can help so many animals, I feel a great responsibility to them to make this company go.”
For more information about PetVivo Cares please contact firstname.lastname@example.org or visit https://petvivo.com/
Veterinary Meeting & Expo (VMX) Conference
Booth #: 2030
Sunday, January 20, 2019 9:00am – 5:30pm
Monday, January 21, 2019 9:00am – 5:30pm
Tuesday, January 22, 2019 9:00am – 5:30pm
Wednesday, January 23, 2019 9:00am – 2:00pm
Location: South Concourse of the Orange County Convention Center
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (OTCPINK: PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.
PetVivo's strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents protects the company’s products, production processes and biomaterials. PetVivo’s lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for launch later this year.
Forward-Looking commercial Statements:
The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements
Petvivo Holdings, Inc.
email us here